Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood test may forecast kidney comeback in dialysis emergencies

NCT ID NCT07637435

First seen Jun 16, 2026 · Last updated Jun 22, 2026 · Updated 1 time

Summary

This completed study looked at 170 adults who needed emergency hemodialysis for acute kidney injury. Researchers measured three blood markers (Activin A, Nostrin, and Angiopoetin-2) before dialysis to see if they could predict whether the kidneys would recover or if the patient would die within 6 months. The goal is to find simple blood tests that help doctors make better treatment decisions for these critically ill patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Mugla Sitki Kocman University

    Muğla, Menteşe, 48000, Turkey (Türkiye)

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this research could help doctors better predict which patients will recover kidney function and who is at higher risk of dying.

What could go wrong

This is an observational study, not a treatment trial. The markers may not prove useful in real-world settings, and results may not apply to all kidney injury patients.

Conditions

The condition(s) this trial relates to.

Acute Kidney Injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.